Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

PARIS--()--Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):

Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at December 31, 2019, settlement date:

  • 341,069 shares
  • €13,897.05 in cash

During the 2nd half of 2019, were negotiated a total of:

BUY   510,522 shares   €327,615.49   656 executions
SALE   380,311 shares   €246,522.48   525 executions

It is recalled that for the last half-year summary as at June 30, 2019, the following resources were included in the liquidity account:

  • 210,858 shares
  • €95,092.53 in cash

During the 1st half of 2019, were negotiated a total of:

BUY   551,475 shares   €486,463.73   866 executions
SALE   451,712 shares   €404,963.46   711 executions

It is also recalled that when the contract was set up on December 3, 2018, the following resources had been allocated to the liquidity account:

  • 87,612 shares
  • €196,423.24 in cash

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

Onxeo’s portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq® (belinostat IV form).

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 “Risk Factors” ("Facteurs de Risque") of the 2018 registration document filed with the Autorité des marchés financiers on April 25, 2019 under number D.19-0282, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company’s website (www.onxeo.com).

APPENDIX

    Buy Side   Sell Side
  Number of executions   Number of shares   Traded volume in EUR Number of executions     Number of shares   Traded volume in EUR
Total   656   510,522   327,615.49 525     380,311   246,522.48
01/07/2019   4   4,000   3,160.00 42     28,493   22,794.40
02/07/2019   3   2,000   1,580.00 3     2,001   1,620.81
08/07/2019   4   3,000   2,370.00 -     -   -
09/07/2019   8   6,001   4,680.78 1     1   0.79
10/07/2019   6   5,000   3,850.00 -     -   -
11/07/2019   2   1,001   770.77 4     2,001   1,560.78
12/07/2019   5   4,250   3,272.50 2     1,004   783.12
15/07/2019   3   751   578.27 1     1   0.77
16/07/2019   2   2,000   1,520.00 1     749   576.73
18/07/2019   22   17,296   12,972.00 1     1   0.76
19/07/2019   4   1,705   1,261.70 2     275   206.25
22/07/2019   11   9,000   6,570.00 1     1   0.73
23/07/2019   6   5,922   4,204.62 18     9,999   7,299.27
24/07/2019   3   2,000   1,460.00 5     2,422   1,792.28
25/07/2019   2   958   728.08 29     22,304   16,951.04
26/07/2019   20   16,043   12,032.25 -     -   -
29/07/2019   2   1,000   740.00 -     -   -
30/07/2019   4   3,001   2,190.73 1     1   0.74
01/08/2019   9   6,000   4,320.00 -     -   -
02/08/2019   4   2,078   1,475.38 -     -   -
05/08/2019   14   12,000   8,520.00 2     1,000   710.00
06/08/2019   1   144   100.80 2     1,000   710.00
07/08/2019   7   6,856   4,799.20 -     -   -
08/08/2019   11   4,000   2,800.00 -     -   -
09/08/2019   18   29,001   20,300.70 16     19,850   14,292.00
12/08/2019   11   9,946   6,862.74 3     3,000   2,100.00
13/08/2019   21   16,317   11,095.56 14     9,047   6,332.90
14/08/2019   23   18,738   12,929.22 28     19,155   13,600.05
15/08/2019   22   24,000   15,840.00 -     -   -
16/08/2019   2   2,000   1,300.00 12     10,000   6,700.00
19/08/2019   -   -   - 8     7,000   4,760.00
20/08/2019   1   491   333.88 5     4,000   2,760.00
21/08/2019   5   4,000   2,760.00 5     4,000   2,800.00
22/08/2019   5   3,509   2,386.12 -     -   -
23/08/2019   7   5,001   3,350.67 4     2,201   1,496.68
26/08/2019   2   1,000   670.00 -     -   -
27/08/2019   2   186   124.62 1     1   0.67
28/08/2019   1   1   0.68 1     1   0.68
29/08/2019   11   6,125   4,042.50 -     -   -
30/08/2019   6   2,690   1,748.50 -     -   -
02/09/2019   3   3,000   1,980.00 11     7,015   4,700.05
03/09/2019   8   4,355   2,874.30 -     -   -
04/09/2019   2   645   419.25 -     -   -
05/09/2019   1   1,000   650.00 -     -   -
06/09/2019   3   2,001   1,300.65 1     1   0.65
09/09/2019   6   3,000   1,920.00 -     -   -
10/09/2019   6   6,000   3,840.00 12     9,000   5,940.00
11/09/2019   6   4,000   2,560.00 -     -   -
12/09/2019   17   22,999   14,259.38 -     -   -
13/09/2019   -   -   - 7     5,000   3,150.00
16/09/2019   -   -   - 1     1,000   630.00
17/09/2019   11   9,245   5,824.35 6       5,374   3,439.36
18/09/2019   12   6,755   4,188.10 5   4,000   2,520.00
19/09/2019   4   3,000   1,950.00 35   30,411   20,375.37
20/09/2019   18   15,000   9,450.00 -   -   -
23/09/2019   5   5,000   3,100.00 -   -   -
24/09/2019   1   1,000   610.00 -   -   -
25/09/2019   4   3,000   1,830.00 -   -   -
26/09/2019   1   81   49.41 -   -   -
27/09/2019   7   4,920   3,001.20 1   1   0.61
30/09/2019   1   1,000   600.00 2   1,254   777.48
01/10/2019   2   6,000   3,600.00 1   746   462.52
02/10/2019   2   2,000   1,200.00 -   -   -
03/10/2019   7   9,000   5,310.00 -   -   -
04/10/2019   2   1,592   923.36 -   -   -
07/10/2019   4   2,408   1,348.48 -   -   -
08/10/2019   1   1,000   540.00 -   -   -
09/10/2019   1   1   0.54 1   1   0.54
10/10/2019   1   1,000   530.00 -   -   -
11/10/2019   1   1,000   520.00 -   -   -
14/10/2019   3   2,000   1,000.00 -   -   -
15/10/2019   -   -   - 8   7,000   3,920.00
16/10/2019   -   -   - 14   12,000   7,200.00
17/10/2019   1   2,000   1,160.00 -   -   -
18/10/2019   1   1,000   560.00 -   -   -
21/10/2019   21   14,000   7,840.00 1   1,000   560.00
22/10/2019   1   1   0.55 1   1   0.55
23/10/2019   -   -   - 13   13,000   7,410.00
24/10/2019   13   8,301   4,648.56 2   376   214.32
25/10/2019   10   3,700   1,998.00 -   -   -
28/10/2019   2   2,000   1,080.00 -   -   -
29/10/2019   1   1   0.54 1   1   0.54
30/10/2019   -   -   - 1   1,000   550.00
31/10/2019   5   2,001   1,060.53 1   1   0.55
01/11/2019   3   2,001   1,040.52 5   3,672   1,982.88
04/11/2019   -   -   - 5   1,329   717.66
05/11/2019   3   3,000   1,650.00 5   4,000   2,240.00
06/11/2019   6   5,000   2,750.00 8   6,625   3,710.00
07/11/2019   6   3,000   1,650.00 2   1,001   560.56
08/11/2019   -   -   - 3   999   559.44
11/11/2019   1   1,000   550.00 1   1   0.56
12/11/2019   2   2,000   1,100.00 2   1,999   1,119.44
13/11/2019   8   6,000   3,300.00 10   7,963   4,459.28
14/11/2019   13   9,525   5,524.50 44   31,528   18,601.52
15/11/2019   18   14,475   8,250.75 -   -   -
18/11/2019   2   2,000   1,120.00 -   -   -
19/11/2019   14   8,152   4,646.64 15   15,000   8,700.00
20/11/2019   10   6,848   3,834.88 1   1,000   560.00
21/11/2019   3   3,000   1,650.00 1   1,000   570.00
22/11/2019   2   2,000   1,100.00 7   3,000   1,650.00
25/11/2019   2   2,000   1,100.00 8   2,545   1,425.20
26/11/2019   8   4,454   2,449.70 5   3,455   1,934.80
27/11/2019   4   1,929   1,060.95 1   1   0.56
28/11/2019   1   1   0.55 3   2,001   1,120.56
29/11/2019   6   4,100   2,255.00 1   500   275.00
02/12/2019   3   2,517   1,359.18 -   -   -
03/12/2019   1   1   0.53 1   1   0.53
04/12/2019   12   5,001   2,650.53 1   1   0.53
05/12/2019   3   2,000   1,040.00 5   2,500   1,325.00
06/12/2019   1   500   265.00 4   4,000   2,160.00
09/12/2019   6   3,605   1,910.65 1   1   0.55
10/12/2019   2   1,395   725.40 -   -   -
11/12/2019   1   1   0.52 1   1   0.52
12/12/2019   8   5,463   2,950.02 19   15,588   8,573.40
13/12/2019   3   3,000   1,620.00 -   -   -
16/12/2019   3   2,489   1,344.06 -   -   -
17/12/2019   5   3,168   1,679.04 -   -   -
18/12/2019   2   1,880   977.60 -   -   -
19/12/2019   -   -   - 2   1,000   540.00
23/12/2019   2   2,000   1,040.00 -   -   -
27/12/2019   1   1,000   510.00 -   -   -
30/12/2019   -   -   - 1   1,000   530.00
31/12/2019   2   2,000   1,080.00 26   20,910   11,500.50

A Public Limited Company with Share Capital of 12,683,913.25 euros
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris
Paris Trade and Companies’ Register 410 910 095

Contacts

Onxeo
Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations
Nicolas Merigeau
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98

Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Investor Relations US
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578

Contacts

Onxeo
Valerie Leroy,
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00

Media Relations
Nicolas Merigeau
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98

Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92

Investor Relations US
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
+1 212 915 2578